BRPI1013432A2 - derivado de indolizina e uso do mesmo para propósitos médicos - Google Patents

derivado de indolizina e uso do mesmo para propósitos médicos

Info

Publication number
BRPI1013432A2
BRPI1013432A2 BRPI1013432A BRPI1013432A BRPI1013432A2 BR PI1013432 A2 BRPI1013432 A2 BR PI1013432A2 BR PI1013432 A BRPI1013432 A BR PI1013432A BR PI1013432 A BRPI1013432 A BR PI1013432A BR PI1013432 A2 BRPI1013432 A2 BR PI1013432A2
Authority
BR
Brazil
Prior art keywords
medical purposes
indolizine derivative
indolizine
derivative
medical
Prior art date
Application number
BRPI1013432A
Other languages
English (en)
Inventor
Kazuo Shimizu
Masato Iizuka
Yasushi Takigawa
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BRPI1013432A2 publication Critical patent/BRPI1013432A2/pt
Publication of BRPI1013432B1 publication Critical patent/BRPI1013432B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1013432A 2009-03-31 2010-03-30 derivado de indolizina e composição farmacêutica BRPI1013432B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009086306 2009-03-31
JP2009279976 2009-12-10
PCT/JP2010/055692 WO2010113942A1 (ja) 2009-03-31 2010-03-30 インドリジン誘導体及びその医薬用途

Publications (2)

Publication Number Publication Date
BRPI1013432A2 true BRPI1013432A2 (pt) 2016-04-05
BRPI1013432B1 BRPI1013432B1 (pt) 2019-12-17

Family

ID=42828231

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013432A BRPI1013432B1 (pt) 2009-03-31 2010-03-30 derivado de indolizina e composição farmacêutica

Country Status (20)

Country Link
US (1) US8748452B2 (pt)
EP (1) EP2415771B1 (pt)
JP (1) JP5638513B2 (pt)
KR (1) KR101772963B1 (pt)
CN (1) CN102365281B (pt)
AU (1) AU2010231615B2 (pt)
BR (1) BRPI1013432B1 (pt)
CA (1) CA2755132C (pt)
CY (1) CY1114520T1 (pt)
DK (1) DK2415771T3 (pt)
ES (1) ES2429148T3 (pt)
HR (1) HRP20130846T1 (pt)
MX (1) MX2011010395A (pt)
PL (1) PL2415771T3 (pt)
PT (1) PT2415771E (pt)
RU (1) RU2529868C2 (pt)
SI (1) SI2415771T1 (pt)
TW (1) TWI471325B (pt)
WO (1) WO2010113942A1 (pt)
ZA (1) ZA201107085B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130099064A (ko) * 2010-09-29 2013-09-05 깃세이 야쿠힌 고교 가부시키가이샤 (아자)인돌리진 유도체 및 그 의약용도
NO2686520T3 (pt) 2011-06-06 2018-03-17
CN103889989B (zh) 2011-08-24 2016-01-20 橘生药品工业株式会社 稠合杂环衍生物及其制药用途
RU2627591C2 (ru) 2012-10-23 2017-08-09 Тейдзин Фарма Лимитед Терапевтический или профилактический агент для синдрома распада опухоли
CA2913755A1 (en) * 2013-05-31 2014-12-04 Teijin Pharma Limited Methods of treatment and compositions with xanthine oxidase inhibitors
SG11201509998WA (en) 2013-06-13 2016-01-28 Akebia Therapeutics Inc Compositions and methods for treating anemia
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
BR112016018555B1 (pt) 2014-02-13 2024-01-23 Incyte Holdings Corporation Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
TWI836883B (zh) 2015-04-01 2024-03-21 美商阿克比治療有限公司 用於治療貧血之組合物及方法
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocíclicos como inhibidores LSD1
CN110402244B (zh) 2015-08-12 2023-02-03 因赛特公司 Lsd1抑制剂的盐
EP3344604B1 (en) 2015-09-02 2020-11-04 Sunshine Lake Pharma Co., Ltd. Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof
WO2017114352A1 (en) * 2015-12-28 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Indolizine derivatives, composition and methods of use
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
AU2017323112B2 (en) * 2016-09-07 2020-11-26 Haihe Biopharma Co., Ltd. Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
JP2023052711A (ja) * 2020-03-04 2023-04-12 国立研究開発法人理化学研究所 化合物を放出する方法
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
CN115785018A (zh) * 2022-12-26 2023-03-14 湖北广济药业股份有限公司 一种非布司他脱羧杂质的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2779724B1 (fr) * 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
WO2007043457A1 (ja) 2005-10-07 2007-04-19 Astellas Pharma Inc. トリアリールカルボン酸誘導体
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
CN101679244B (zh) 2007-04-11 2014-01-01 橘生药品工业株式会社 5元杂环衍生物及其医药用途
JP5330990B2 (ja) 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 含窒素複素環化合物およびそれを含有する医薬組成物
AU2008239017B2 (en) * 2007-04-11 2012-09-27 Kissei Pharmaceutical Co., Ltd. (Aza)indole derivative and use thereof for medical purposes

Also Published As

Publication number Publication date
RU2011143741A (ru) 2013-05-10
WO2010113942A1 (ja) 2010-10-07
CN102365281A (zh) 2012-02-29
ZA201107085B (en) 2012-12-27
TWI471325B (zh) 2015-02-01
AU2010231615A1 (en) 2011-11-03
JPWO2010113942A1 (ja) 2012-10-11
KR20110132599A (ko) 2011-12-08
PT2415771E (pt) 2013-10-03
SI2415771T1 (sl) 2013-12-31
EP2415771B1 (en) 2013-07-31
CA2755132A1 (en) 2010-10-07
RU2529868C2 (ru) 2014-10-10
US8748452B2 (en) 2014-06-10
JP5638513B2 (ja) 2014-12-10
DK2415771T3 (da) 2013-10-14
HRP20130846T1 (hr) 2013-11-22
MX2011010395A (es) 2011-10-24
CA2755132C (en) 2018-02-13
KR101772963B1 (ko) 2017-08-31
PL2415771T3 (pl) 2014-01-31
EP2415771A4 (en) 2012-08-29
AU2010231615B2 (en) 2014-05-15
BRPI1013432B1 (pt) 2019-12-17
CY1114520T1 (el) 2016-10-05
US20120015972A1 (en) 2012-01-19
HK1165793A1 (en) 2012-10-12
EP2415771A1 (en) 2012-02-08
TW201040178A (en) 2010-11-16
ES2429148T3 (es) 2013-11-13
CN102365281B (zh) 2014-11-12

Similar Documents

Publication Publication Date Title
BRPI1013432A2 (pt) derivado de indolizina e uso do mesmo para propósitos médicos
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BR112012013148A2 (pt) formulação farmacêutica e uso
BRPI1010595A2 (pt) cateteres de aterectomia facilmente limpaveis e metodos para uso
BR112013008410A2 (pt) sistema para uso em reparação tecidual
BR112012009021A2 (pt) dispositivo de cuidados para tecidos
HRP20180497T1 (hr) Antimikrobni pripravci i odgovarajući postupci njihove upotrebe
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI1007915A2 (pt) Genes de variante axmi-r1 delta-endotoxina e métodos para seu uso
BRPI0820556A2 (pt) Bactéria e métodos para uso das mesmas
BRPI0914034A2 (pt) dispositivo para limpeza de piso e método de limpeza de um piso
BRPI0919465A2 (pt) dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo
BR112012010991A2 (pt) âncoras de implante e cabelo e sistemas e métodos para seu uso
BR112012000114A2 (pt) arcabouço biodegradável para regeneração de tecido mole e uso do mesmo
UY33132A (es) Proteínas solubles para su uso terapéutico
EP2515946A4 (en) NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0906444A2 (pt) Compostos de 4-piridinona e seu uso para câncer
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto
BR112013014751A2 (pt) sistema de manta para esterilização e métodos de uso
BRPI1010859A2 (pt) aptâmero para quimase, e uso do mesmo
BR112012030927A2 (pt) fosfaplatinas e seu uso para o tratamento de cânceres

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2664 DE 25-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.